Radar · Immunology in California
Best Immunology Companies in California, United States
The 214 best Immunology companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Eikon.
By Riya SenguptaFinancials
214companies tracked
$13.4Bdisclosed funding
2unicorns
155have raised
Ranked: Best Immunology companies in California
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Eikon 🦄 Protein tracking and measuring tool for drug discovery 60Funding top 14%News top 28%Moat top 28%Market top 38% All 10 signals ▾Fundingtop 14% Newstop 28% Moattop 28% Markettop 38% Growthtop 40% Techtop 43% Talenttop 44% Globalbottom 42% Patentsbottom 38% Innovationbottom 36% Funding: Raised $668M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) News: 8 BI events in 12 mo (of 23 tracked, 7 types) · +14% YoY rank vs industry peers · Fliar Intelligence Index 60/100 | $668M | 16 mo ago | Public | 331 | Robert Tjian Co-Founder | 9 patents Automated vehicle intrusion barriers for rapid security deployment | — |
| 2 | ACELYRIN Developer of drugs for immunology | $550M | 45 mo ago | Public | 113 | — | 20 patents Therapeutic antibodies targeting inflammatory pathways for autoimmune skin and joint diseases | — |
| 3 | Alumis Developer of therapeutics for the treatment of auto-immune disease | $529M | 23 mo ago | Public | 16 | Martin Babler CEO | 88 patents TYK2 kinase inhibitor compounds and formulations for inflammatory disease treatment. | — |
| 4 | Mirador Developer of therapeutics for immune-mediated inflammatory and fibrotic diseases 50Funding top 15%Growth top 35%Moat top 42%Tech top 44% All 9 signals ▾Fundingtop 15% Growthtop 35% Moattop 42% Techtop 44% Producttop 49% Talentbottom 49% Newsbottom 38% Globalbottom 36% Marketbottom 32% Funding: Raised $480M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 50/100 | $480M | 5 mo ago | Series B | — | Mark McKenna Founder & CEO | — | — |
| 5 | 180 Life Sciences Developer of drugs for treating inflammatory diseases | $440M | 10 mo ago | Public | 7 | — | — | — |
| 6 | Kyverna Therapeutics Developer of T-cell therapy for autoimmune disease | $322M | 34 mo ago | Public | 96 96 → 160 (+67%) | — | — | — |
| 7 | Orca Bio 🦄 Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders 74Funding top 18%Growth top 26%Moat top 26%Talent top 38% All 8 signals ▾Fundingtop 18% Growthtop 26% Moattop 26% Talenttop 38% Techtop 40% Markettop 42% Globalbottom 37% Newsbottom 18% Funding: Raised $300M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) Growth: Headcount 39 → 66 (+69%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $300M | 5 mo ago | Series F | 66 | Jeroen Bekaert Co-Founder & COO | — | 1 expansion |
| 8 | BioAge Labs Provider of a bioinformatics platform for biomarkers and drug discovery | $294M | 28 mo ago | Public | 43 43 → 100 (+133%) | — | 101 patents NLRP3 inflammasome inhibitors and apelin receptor modulators for BBB, muscle, weight therapies | 1 launch |
| 9 | Arrowhead Pharmaceuticals Developer of therapeutics to treat multiple diseases | $290M | 12 mo ago | Acquired | 427 427 → 809 (+89%) | Christopher Anzalone CEO & President | 1,202 patents RNA interference therapeutics targeting disease genes and targeted delivery systems | — |
| 10 | Sorrento Therapeutics Developer of immuno therapeutics for cancer, inflammation, and autoimmune diseases 67Funding top 20%Patents top 20%Market top 26%Moat top 30% All 12 signals ▾Fundingtop 20% Patentstop 20% Markettop 26% Moattop 30% Innovationtop 32% Growthtop 45% Fin. healthtop 45% Partnerstop 45% Talentbottom 49% Globalbottom 44% Techbottom 31% Newsbottom 27% Funding: Raised $282M across 17 rounds · 17 rounds over 17 yrs (1.0/yr) Patents: 1,073 patents matched (strict assignee match) · 312 filings since 2022 vs 587 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $282M | 14 mo ago | Public | 949 | Henry Ji Co-Founder & CEO | 1,073 patents Patents concentrated in health & consumer products | — |
| 11 | Evommune Developer of therapeutic options for chronic inflammatory disorders 60Growth top 16%Funding top 18%News top 25%Tech top 47% All 10 signals ▾Growthtop 16% Fundingtop 18% Newstop 25% Techtop 47% Fin. healthtop 47% Moattop 47% Patentsbottom 47% Marketbottom 46% Innovationbottom 42% Globalbottom 39% Growth: Revenue +86% YoY · Fresh capital in last 24 mo Funding: Raised $268M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $268M | 4 mo ago | Public | 33 | — | 3 patents Small-molecule PKCθ inhibitors for immune‑modulating therapeutics | 2 launchs · 1 partnership |
| 12 | Septerna Developer of GPCR drug discovery platform for multiple diseases | $250M | 35 mo ago | Public | 53 | Jeff Finer CEO and Co-Founder | 47 patents Small‑molecule agonists/antagonists of PTH1R and Mrgprx2 for bone and allergy therapies | — |
| 13 | SetPoint Medical Developer of implantable neuromodulation devices for inflammatory diseases 72Funding top 18%Product top 18%Innovation top 19%Patents top 22% All 10 signals ▾Fundingtop 18% Producttop 18% Innovationtop 19% Patentstop 22% Growthtop 24% Newstop 24% Moattop 26% Techtop 49% Globalbottom 42% Marketbottom 40% Funding: Raised $248M across 11 rounds · 11 rounds over 17 yrs (0.6/yr) Product: 8 distinct product lines · Company stage: Series F rank vs industry peers · Fliar Intelligence Index 72/100 | $248M | 14 mo ago | Series F | 46 | — | 157 patents Bioelectronic neuromodulation devices targeting vagus nerve for chronic inflammation control | 1 launch · 1 partnership |
| 14 | Lycia Therapeutics Developer of protein degradation drugs for the treatment of cancer and auto-immune disease | $227M | 25 mo ago | Series C | 22 22 → 37 (+68%) | Carolyn Bertozzi Founder | — | — |
| 15 | Candid Therapeutics Developer of therapeutics for autoimmune diseases 40Funding top 17%Growth top 38%News top 48%Moat top 48% All 8 signals ▾Fundingtop 17% Growthtop 38% Newstop 48% Moattop 48% Talentbottom 49% Techbottom 38% Globalbottom 38% Marketbottom 32% Funding: Raised $206M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $206M | 3 mo ago | Acquired | — | Ken Song CEO | — | — |
| 16 | Eledon Provider of therapeutics solution for organ or cellular transplantation in autoimmune and neurodegenerative… | $201M | 25 mo ago | Public | 17 17 → 42 (+147%) | — | — | — |
| 17 | Attralus Developer of drugs for the treatment of Amyloid diseases | $197M | 28 mo ago | Series B | 23 | Jonathan Wall Co-Founder | 50 patents Engineered Fc‑fusion and antibody‑peptide biologics for amyloid disease therapy | — |
| 18 | Sudo Biosciences Developer of therapeutics for immune-mediated inflammatory conditions | $183M | 28 mo ago | Series B | 11 | Scott Byrd CEO | — | — |
| 19 | Santa Ana Bio Developer of precision medicines for autoimmune diseases. | $168M | 25 mo ago | Series B | 25 | Danny Wells Co-Founder | — | — |
| 20 | Ventyx Biosciences Developer of therapeutics to treat autoimmune diseases | $165M | 20 mo ago | Acquired | 79 | Raju Mohan Founder & CEO | 54 patents TYK2 kinase inhibitor design, synthesis, and crystalline forms for immunomodulatory therapeutics | — |
| 21 | Ouro Medicines Developer of therapeutics for people living with chronic immune-mediated diseases | $120M | 17 mo ago | Acquired | — | Jaideep Dudani CEO | — | — |
| 22 | RegCell Developer of cell therapies focused on restoring immune tolerance for autoimmune diseases | $117M | 15 mo ago | Seed | — | Shimon Sakaguchi Founder | — | — |
| 23 | RayThera Developer of small molecule therapies for unmet needs in immunology | $110M | 14 mo ago | Series A | — | Gene Hung Co-Founder & CSO | 12 patents Peptide-based modulators targeting Jak2 V617F, TNF‑α, CCR4, and STAT6 signaling | — |
| 24 | CalciMedica Developer of CRAC channel inhibitor drugs for inflammatory diseases | $87M | 14 mo ago | Public | 11 | — | 271 patents CRAC channel inhibitor drugs for inflammatory lung and pancreatic disorders | — |
| 25 | TRexBio Developer of therapeutics for immunology and cancer 45Funding top 20%Moat top 31%News top 46%Talent bottom 49% All 6 signals ▾Fundingtop 20% Moattop 31% Newstop 46% Talentbottom 49% Marketbottom 47% Globalbottom 36% Funding: Raised $85.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 45/100 | $85M | 4 mo ago | Series B | 65 | Johnston Erwin CEO | — | — |
| 26 | Electra Therapeutics Developer of therapies for immunological diseases and cancer | $84M | 8 mo ago | Series C | 4 | Adam Rosenthal Co-Founder & CEO | — | 1 launch |
| 27 | Tr1X Developer of T cell-based products to treat autoimmune and inflammatory diseases | $75M | 14 mo ago | Series A | 7 | David Vries Co-Founder | 35 patents IL-10‑secreting CD4+ CAR‑T cell immunotherapies for enhanced immune regulation | — |
| 28 | EpiBiologics Developer of antibody-based targeted therapies to treat multiple diseases 45Funding top 21%Talent top 38%Moat top 39%Innovation top 42% All 7 signals ▾Fundingtop 21% Talenttop 38% Moattop 39% Innovationtop 42% Patentstop 42% Globalbottom 37% Marketbottom 34% Funding: Raised $73.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $73M | 5 mo ago | Series B | 22 | Josef Gramespacher Co-Founder | 13 patents Bispecific antibody therapeutics for targeted degradation of EGFR and cMET receptors | 1 job opening |
| 29 | Excellergy Developer of trifunctional effector cell response inhibitors for allergic diseases | $70M | 8 mo ago | Acquired | — | Theodore Jardetzky Co-Founder | 5 patents Therapeutic antibodies and fragments that bind IgE for allergy treatment | — |
| 30 | Therini Bio Limited information available | $62M | 13 mo ago | Series A | 13 13 → 15 (+15%) | Daniel Burgess CEO | — | — |
| 31 | Nuvig Therapeutics Developer of therapeutics to treat inflammatory and autoimmune diseases | $47M | 18 mo ago | Series B | 10 | Greg Coffey Co-Founder | — | — |
| 32 | Arda Therapeutics Developer of therapeutics to remove pathological cells which are the root causes of chronic diseases | $43M | 20 mo ago | Series A | 5 | Adam Freund Founder & CEO | — | — |
| 33 | Siolta Therapeutics Provider of microbiome therapeutics for treating multiple diseases | $42M | 27 mo ago | Series C | 14 | Nikole Kimes Founder & CEO | — | — |
| 34 | Equillium Developer of therapies for treating autoimmune and inflammatory disorders | $30M | 10 mo ago | Public | 36 36 → 38 (+6%) | Daniel Bradbury Co-Founder & CEO | 33 patents Immunotherapy antibodies targeting CD6 for autoimmune and inflammatory disease treatment | — |
| 35 | Athos Therapeutics Developer of AI-based therapeutics for treating autoimmune diseases 35AI top 35%Funding top 36%Talent bottom 49%Moat bottom 45% All 6 signals ▾AItop 35% Fundingtop 36% Talentbottom 49% Moatbottom 45% Marketbottom 32% Globalbottom 25% AI: Product described with: ai-based, machine learning Funding: Raised $28.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $28M | 2 mo ago | Series A | 18 | Dimitrios Iliopoulos Co-founder | — | — |
| 36 | Boomerang Medical Bioelectronic device technology for the treatment of autoimmune diseases | $18M | 9 mo ago | Series B | 5 | — | — | 1 internship |
| 37 | GEn1E Developer of therapeutics for the treatment of inflammatory and rare diseases | $17M | 7 mo ago | Series A | 19 | Ritu Lal Co-Founder & CEO | — | — |
| 38 | SmartHealth Developer precision diagnostics for vascular, metabolic, and oncological diseases | $17M | 19 mo ago | Series B | 17 | Larry Dentice CEO | 44 patents Coating and dispensing technologies for medical patches and low‑volume drug packaging | — |
| 39 | SelectION Provider of screening and development platform for drugs 11Funding top 36%Talent bottom 49%Global bottom 37%Market bottom 17% All 4 signals ▾Fundingtop 36% Talentbottom 49% Globalbottom 37% Marketbottom 17% Funding: Raised $15.9M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $16M | 9 mo ago | Series A | 2 | Andreas Klostermann Founder & CSO | — | — |
| 40 | Iolyx Therapeutics Developer of therapeutics for autoimmunity and ophthalmological conditions | $15M | 6 mo ago | Series B | — | Elizabeth Jeffords CEO & President | — | — |
| 41 | ParcelBio Developer of programmable technology to deliver mRNA to diverse cell types in the body | $13M | 4 mo ago | Seed | — | Christopher Carlson Co-Founder | — | — |
| 42 | NovoMedix Early-stage Biopharma company developing orally-available small molecule drugs for fibrosis-related… | $9M | 17 mo ago | Funding Raised | 4 | Cathy Swindlehurst Founder & CEO | 56 patents Small-molecule biaryl sulfonamide drugs for treating pulmonary fibrosis | — |
| 43 | Luxvitae Therapeutics Developer of therapeutics for multiple diseases | $8M | 18 mo ago | Series A | — | Mathew Patt Founder | — | — |
| 44 | TippingPoint Biosciences Developer of therapeutics for treating diseases caused by dysfunctional genome chromatin packaging | $7M | 2 mo ago | Seed | — | Geeta Narlikar Co-Founder | — | 1 partnership |
| 45 | Apeximmune Therapeutics Developer of biologics for cancer and auto-immune disease | $6M | 14 mo ago | Series A | 3 | — | — | — |
| 46 | Tega Therapeutics Glycoscience company developing heparan sulfate therapies and enzyme replacement therapy | $4M | 7 mo ago | Funding Raised | 7 | — | — | — |
| 47 | SiftBio Developer of peptide immunotherapies for cancer and autoimmune diseases | $4M | 6 mo ago | Seed | — | Maddie Williams Co-Founder & CTO | — | — |
| 48 | Inflammatory Response Research Innovating clinical medicine for inflammatory disorders and conditions | $2M | 12 mo ago | Seed | — | Chandler May CEO | — | — |
| 49 | Hillhurst Biopharmaceuticals Developer of carbon monoxide based therapeutics | $2M | 6 mo ago | Seed | — | Andrew Gomperts CEO & President | — | — |
| 50 | Ditto Biosciences Developer of therapies targeting autoimmune diseases by leveraging parasite biology | $500K | 5 mo ago | Seed | — | Emily Weiss Co-Founder & CTO | — | — |
Top 12 Immunology companies in California
#1
Public · Sacramento, California · founded 2020 · 33 employees$268Mraised▾
Public · Sacramento, California · founded 2020 · 33 employees
Developer of therapeutic options for chronic inflammatory disorders. The pipeline drug candidates include v for rosacea, and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCϴ for atopic dermatitis. The company uses a tissue-based screening platform that helps in the drug development of inflammatory diseases.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Growth
top 16%Funding
top 18%News
top 25%Tech
top 47%Fin. health
top 47%Moat
top 47%Growth: Revenue +86% YoY · Fresh capital in last 24 mo
Funding: Raised $268M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) · Last round Post IPO (Feb 2026)
News: 15 BI events in 12 mo (of 26 tracked, 6 types) · +650% YoY · 14 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 2 product launches · 1 partnerships (incl. Maruho Co Ltd.) announced in 12 mo
Funding rounds
- Feb 2026Post IPO$125M
- Oct 2024Series C$115M
- Jun 2023Series B$7.5M
- Mar 2023Series B$57.5M
Investors
Andera Partners, Life Sciences Partners, Pivotal bioVenture Partners, RA Capital Management, Sectoral, RTW Investments
Tech stack
Amazon Web ServicesAosApache Http ServerBootstrapCloudflareCloudflare Bot Management
#2
Series B · San Diego, California · founded 2023$480Mraised▾
Series B · San Diego, California · founded 2023
Developer of therapeutics for immune-mediated inflammatory and fibrotic diseases. The company’s Mirador360 precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 15%Growth
top 35%Moat
top 42%Tech
top 44%Product
top 49%Talent
bottom 49%Funding: Raised $480M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Jan 2026)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 119 LinkedIn followers
Funding rounds
- Jan 2026Series B$250M
- Feb 2024Series A$400M
- Dec 2023Seed$80M
Founders & team
Investors
Arch Venture Partners, Orbimed, Fairmount Partners, Sanofi, Point72 Ventures, Farallon Capital Management
Tech stack
AddtoanyAmazon CloudfrontAmazon Web ServicesApache Http ServerApple Icloud MailCookiebot
#3
Acquired · San Diego, California · founded 2024$206.2Mraised▾
Acquired · San Diego, California · founded 2024
Developer of therapeutics for autoimmune diseases. It focuses on identifying and targeting specific pathways to develop therapies which include CND106 a bispecific antibody that targets and eliminate later stage B-cellsf or autoantibody disease treatment, CND261 targets a broad range of B-cell subtypes for autoimmune diseases.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 17%Growth
top 38%News
top 48%Moat
top 48%Talent
bottom 49%Tech
bottom 38%Funding: Raised $206M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series E (Mar 2026)
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
News: 4 BI events in 12 mo (of 8 tracked, 2 types) · +0% YoY · Top themes: M&A
Audience (LinkedIn): 9k LinkedIn followers — 2.4% of this cohort's audience
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- Mar 2026Series E$505M
- Sep 2024Series D$370M
Founders & team
Investors
Venrock, Fairmont, TCG Crossover, VenBio, Foresite Capital, Third Rock Ventures
Tech stack
CloudflareCloudflare Bot ManagementDreamhostGoogle Font ApiHttp/3Jquery
#4
Orca Bio 🦄Series F · Menlo Park, California · founded 2016 · 66 employees$300Mraised▾
Orca Bio 🦄
Series F · Menlo Park, California · founded 2016 · 66 employees
Orca Bio is a developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders. It uses OrcaSort technology that is an enabling feature for the scalability and high-precision of the manufacturing platform. It also helps in the isolation and purification of stem cells and immune cells used in hematopoietic cell grafts. The components of the technology are optimized for performance and designed to fit seamlessly into the clinical processing of apheresis products. It has developed therapeutic solutions for regulatory T cells that aims to temper the immune reaction. It reduces the fatal complications and provides maximum control of the development of the patient's new immune system.
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Funding
top 18%Growth
top 26%Moat
top 26%Talent
top 38%Tech
top 40%Market
top 42%Funding: Raised $300M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) · Last round Series F (Jan 2026)
Growth: Headcount 39 → 66 (+69%) across vintages · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 9/10 · Unicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 6.8% of this cohort's audience · 158 engagements/post (1.9× cohort median)
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- Jan 2026Series F$250M
- Nov 2019Series D$192M
Founders & team
Investors
Lightspeed Venture Partners, 8VC, DCVC, ND Capital, IMRF, Kaiser Permanente
Tech stack
Amazon Web ServicesApple Icloud MailBackbone.JsBrizy WordpressBunnyBunny Fonts
#5
Series B · San Francisco, California · founded 2019 · 65 employees$85Mraised▾
Series B · San Francisco, California · founded 2019 · 65 employees
Developer of therapeutics for immunology and cancer. The company is developing transformative therapies by using a technology that maps human tissue and manipulates Tregs and other immune cells in a tissue-specific and disease-specific fashion.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 20%Moat
top 31%News
top 46%Talent
bottom 49%Market
bottom 47%Global
bottom 36%Funding: Raised $85.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series B (Jan 2026)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
News: 2 BI events in 12 mo (of 3 tracked, 3 types) · +100% YoY · Top themes: Announcements, Capital raise
Audience (LinkedIn): 13k LinkedIn followers — 3.5% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Jan 2026Series B$50M
- Nov 2024Series B$84M
- Mar 2022Series A$26M
- Jun 2021Series A$59M
Founders & team
Investors
Polaris Partners, SV Health Investors, Lilly, Johnson & Johnson Innovation, Pfizer, Alexandria
#6
Public · Menlo Park, California · founded 2016 · 7 employees$439.6Mraised▾
Public · Menlo Park, California · founded 2016 · 7 employees
Developer of drugs for treating inflammatory diseases. The company has developed Fibrosis & Anti TNF that helps in treating POCD, NACH, Dupuytren's contracture, frozen shoulder, and others. It also provides SCAs that are in the clinical stage and helps in treating diseases like chronic pain, early arthritis, and others. Its drug candidate q7nAChr provides solutions for smoking cessation-induced ulcerative colitis.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 684 LinkedIn followers
Funding rounds
- Jul 2025Post IPO$425M
- Dec 2024Post IPO$2.9M
- Feb 2021Post IPO$11.7M
Investors
Electric Capital, Polychain, GSR, Omicron Technologies, Harbour Island
#7
Series A · Torrance, California · founded 2019 · 18 employees$28Mraised▾
Series A · Torrance, California · founded 2019 · 18 employees
Developer of AI-based therapeutics for treating autoimmune diseases. The company has developed an innovative computational process based on machine learning algorithms that identify novel and safe drug/gene targets for individual patients. The product pipeline includes ATH-63, ATH-105, and ATH-120 for Ulcerative Colitis & Crohn’s Disease.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
AI
top 35%Funding
top 36%Talent
bottom 49%Moat
bottom 45%Market
bottom 32%Global
bottom 25%AI: Product described with: ai-based, machine learning
Funding: Raised $28.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series A (Apr 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Director of AI & Machine Learning
Funding rounds
- Apr 2026Series A$10.3M
- Jan 2024Series A$7.6M
- Nov 2021Series A$20.4M
Founders & team
#8
Series B · San Carlos, California · founded 2021 · 22 employees$73Mraised▾
Series B · San Carlos, California · founded 2021 · 22 employees
Developer of antibody-based targeted therapies to treat multiple diseases. The company has a proprietary EpiTAC platform that enables the development of first-in-class and best-in-class targeted therapies that degrade disease-driving membrane and extracellular proteins against a wide range of disorders.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 21%Talent
top 38%Moat
top 39%Innovation
top 42%Patents
top 42%Global
bottom 37%Funding: Raised $73.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Jan 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · IP moat: 13 patents · Soonicorn
Audience (LinkedIn): 5k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Mass Spec Scientist Large Molecule Characterization
Funding rounds
- Jan 2026Series B$107M
- Jul 2023Series A$23M
- Mar 2023Series A$50M
Founders & team
Investors
Mubadala, Polaris Partners, Vivo Capital, Google Ventures, Digitalis Ventures, Taiho Ventures
#9
Acquired · Pasadena, California · founded 1989 · 427 employees$290.2Mraised▾
Acquired · Pasadena, California · founded 1989 · 427 employees
Developer of therapeutics to treat multiple diseases. The company develops medicines that treat intractable diseases by silencing the genes that cause them. The company’s pipeline includes ARO-AAT to treat liver diseases, ARO-APOC3 for Hypertriglyceridemia, ARO-ANG3 for Dyslipidemia, and more.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 101k LinkedIn followers — 28.3% of this cohort's audience
Funding rounds
- May 2025Grant (prize money)$305K
- Dec 2017Post IPO$7.2M
- Jan 2017Post IPO$9.7M
- Sep 2016Post IPO$56.5M
Founders & team
Investors
Silence Therapeutics, Orbimed, RA Capital Management, Perceptive Advisors, RTW Investments, Amgen Business Development
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#10
Eikon 🦄Public · Millbrae, California · founded 2019 · 331 employees$668Mraised▾
Eikon 🦄
Public · Millbrae, California · founded 2019 · 331 employees
Protein tracking and measuring tool for drug discovery. The company has developed a therapeutic discovery platform that assists researchers to analyze targeting protein dynamics for the drug discovery process. It uses technology platform that combines live-cell super-resolution microscopy, comuting and engineering.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 14%News
top 28%Moat
top 28%Market
top 38%Growth
top 40%Tech
top 43%Funding: Raised $668M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series D (Feb 2025)
News: 8 BI events in 12 mo (of 23 tracked, 7 types) · +14% YoY · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo
Moat: Editorial + unicorn rating 9/10 · IP moat: 9 patents · Unicorn
Audience (LinkedIn): 32k LinkedIn followers — 9.0% of this cohort's audience · 139 engagements/post (1.7× cohort median)
Funding rounds
- Feb 2025Series D$350.7M
- Jun 2023Series C$140.8M
- Jan 2022Series B$517.8M
- May 2021Series A$148M
Founders & team
Investors
The Column Group, Foresite Capital, Innovation Endeavors, Lux Capital, T. Rowe Price, CPP Investments
Tech stack
Amazon SesAmazon Web ServicesApple Icloud MailCloudflareCloudflare Bot ManagementDocusign
#11
Series C · San Francisco, California · founded 2018 · 4 employees$84Mraised▾
Series C · San Francisco, California · founded 2018 · 4 employees
Developer of therapies for immunological diseases and cancer. The company focuses on the development of therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. The company's lead product ELA026, is a monoclonal antibody to treat secondary hemophagocytic lymphohistiocytosis (sHLH).
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Activity: 1 product launches announced in 12 mo
Funding rounds
- Oct 2025Series C$183M
- Dec 2023Series B—
- Feb 2022Series B$84M
Founders & team
Investors
Westlake Village Biopartners, Orbimed, Redmile Group, Cormorant Asset Management, Cowen, New Leaf Venture Partners
#12
Public · San Diego, California · founded 1989 · 949 employees$281.6Mraised▾
Public · San Diego, California · founded 1989 · 949 employees
Developer of immuno therapeutics for cancer, inflammation, and autoimmune diseases. The company’s lead products are multiple biosimilars and bio better antibodies as well as clinical CAR-T therapies targeting solid tumors. Also, has a portfolio of immuno-oncology antibody programs targeting EGFR, TNF-alpha, CD 25, and IGE. Its lead CAR-T cell therapies are against the carcinoembryonic antigen and prostate-specific membrane antigen.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 20%Patents
top 20%Market
top 26%Moat
top 30%Innovation
top 32%Growth
top 45%Funding: Raised $282M across 17 rounds · 17 rounds over 17 yrs (1.0/yr) · Last round Post IPO (Apr 2025)
Patents: 1,073 patents matched (strict assignee match) · 312 filings since 2022 vs 587 in 2017-21 · Latest publication 2026
Market: 949 employees (top 9% of Immunotherapy) · Revenue ~$62.8M · ~13% of tracked Immunotherapy revenue (13 cos, FY2026)
Funding rounds
- Apr 2025Post IPO$47.4M
- Sep 2018Conventional Debt—
- Jun 2018Post IPO$150M
- Nov 2016Venture Debt$50M
Founders & team
Investors
Aisling Capital, Yuhan Corporation, Hercules Capital, Ally Bridge Group, FREJOY Investment Management, Beijing Shijilongxin Investment
Tech stack
WordpressMysqlPhpTwenty FourteenYoast SeoNginx
Funding & investor landscape
$13.4Btotal disclosed funding
161companies funded
559disclosed rounds
2rounds last 90 days
Most active investors
Y Combinator9 rounds
Notable founders
Mark McKenna
Founder & CEO · Mirador
Ken Song
CEO · Candid Therapeutics
Jeroen Bekaert
Co-Founder & COO · Orca Bio
Ivan Dimov
Co-Founder & Co-CEO · Orca Bio
Johnston Erwin
CEO · TRexBio
Dimitrios Iliopoulos
Co-founder · Athos Therapeutics
Josef Gramespacher
Co-Founder · EpiBiologics
Ann Lee-Karlon
CEO · EpiBiologics
Christopher Anzalone
CEO & President · Arrowhead Pharmaceuticals
Robert Tjian
Co-Founder · Eikon
Luke Lavis
Co-Founder · Eikon
Adam Rosenthal
Co-Founder & CEO · Electra Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 11,202,533 docs
Market landscape — 10 sub-themes by coverage
Share of Immunology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN CALIFORNIA · Health & Bio
How research on Immunology in California is moving
A read on the academic research around Immunology in California — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 922 papers.
UC Los Angeles, San Francisco, and San Diego lead California's immunology research, predominantly advancing CAR-T cell therapy and cancer immunotherapy with a cautiously optimistic tone.
922 papers · stance +0.47 · 32% breakthrough · 17% concern
top institutions
- University of California, Los Angeles180
- University of California, San Francisco175
- University of California San Diego137
- University of Southern California86
- University of California, Irvine69
leading researchers
Yan-Ruide Li · Huang, Alexander · Wang, Guanning · Yuning Chen · Antoni Ribas · Wenxue Ma
prism intelligence · tone & topics
93% positive · 2% critical tone
PharmaceuticalsBiotechnologyClinical TrialsMedical ResearchHealthOncology
▲
Breakthroughs257 · 28%
28%→28% share
▲1.0× share momentum0 median citations86% since 2021mostly methods-led
Cancer immunotherapy research is surging — papers rose from 1 to 37, with T cell and Antibody topics newly emerging.
rising sub-themes (early→recent)
- Immune system5→92
- Immunotherapy11→98
- Chimeric antigen receptor6→42
- Cancer immunotherapy1→37
- Tumor microenvironment1→29
Newly emergingT cell 0→22 · Antibody 0→10 · Autoimmunity 0→9
Landmark Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression · 1,859 cites
◆
Advancements414 · 45%
▼ 51%→45% share
▼0.9× share momentum0 median citations86% since 2021mostly empirical
Immunotherapy advancements are intensifying — papers climbed from 19 to 134, with Clinical trial and Prostate cancer newly emerging.
rising sub-themes (early→recent)
- Immune system13→130
- Immunotherapy19→134
- Cancer5→61
- Tumor microenvironment3→42
- Immune checkpoint2→37
Newly emergingT cell 0→19 · Clinical trial 0→15 · Prostate cancer 0→15
Landmark Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck · 4,969 cites
▼
Concerns142 · 15%
▲ 14%→15% share
▲1.1× share momentum0 median citations85% since 2021mostly reviews
Immunotherapy safety concerns are escalating — papers grew from 4 to 56, with Pembrolizumab and Immune checkpoint newly flagged.
rising sub-themes (early→recent)
- Immunotherapy4→56
- Immune system5→42
- Cancer1→20
- Tumor microenvironment1→19
- Chimeric antigen receptor1→16
Newly emergingCancer immunotherapy 0→11 · Immune checkpoint 0→10 · Pembrolizumab 0→9
Landmark Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Pat · 635 cites
Common questions
How many Immunology companies are there in California, United States?
Radar tracks 214 indexable Immunology companies headquartered in California, United States that meet our profile-completeness bar.
What is the total funding raised by Immunology companies in California, United States?
The Immunology companies in California, United States on this list have raised a combined $13.4B in disclosed equity funding across 161 funded companies.
Which is the highest-funded Immunology company in California, United States?
Eikon is the highest-funded Immunology company in California, United States, with $668M in disclosed equity funding.
How many Immunology companies in California, United States are funded?
161 of the 214 Immunology companies in California, United States on this list have disclosed at least one equity funding round.
How many Immunology unicorns are there in California, United States?
2 Immunology companies in California, United States on this list are valued at $1B or more.
Who are the top investors in California, United States Immunology companies?
The most active investors in California, United States Immunology companies on this list include HHS, Orbimed, Alexandria, Janus Henderson Investors, RA Capital Management.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.